Oxygen Biotech

Oxygen Biotech is developing BAZE-X1, an all-in-one treatment for the patients with severe COVID-19 (SARS-CoV-2)/ ARDS & post-COVID Syndrome (PCS). We follow on from the R&D organization BIOCEV — a joint project of six institutes of the Academy of Sciences of the Czech Republic and two faculties of Charles University in Prague (Faculty of Science and 1st Faculty of Medicine). BAZE-X1 is a patented drug that has „dual-mode“ of action: antiviral immunomodulatory Our team consists of leading Czech scientists, clinicians, and internationally recognized specialists both in the European Union (EU) and the United States of America (USA).